Banque Cantonale Vaudoise Takes $2.07 Million Position in Kenvue Inc. (NYSE:KVUE)

Key Points

• Banque Cantonale Vaudoise acquired 86,281 shares of Kenvue Inc., valued at approximately $2,069,000, during the first quarter, highlighting increasing institutional interest in the company.
• Kenvue has announced a quarterly dividend of $0.2075 per share, representing a yield of 3.82%, up from the previous $0.21 dividend.
• Recent analyst ratings show a consensus of "Hold" for Kenvue, with an average price target lowered to $24.79 amidst decreasing expectations from firms like UBS and Citigroup.

Banque Cantonale Vaudoise acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 86,281 shares of the company's stock, valued at approximately $2,069,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. increased its position in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares during the last quarter. IFP Advisors Inc increased its position in shares of Kenvue by 25.3% in the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock valued at $369,000 after purchasing an additional 3,081 shares during the last quarter. Starboard Value LP purchased a new stake in shares of Kenvue in the 4th quarter valued at approximately $467,864,000. Kingswood Wealth Advisors LLC purchased a new stake in shares of Kenvue in the 1st quarter valued at approximately $413,000. Finally, Cooper Investors PTY Ltd. increased its position in shares of Kenvue by 39.7% in the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock valued at $20,577,000 after purchasing an additional 244,043 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

KVUE traded up $0.16 during midday trading on Friday, reaching $21.60. 13,846,355 shares of the company's stock were exchanged, compared to its average volume of 18,076,148. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $41.44 billion, a PE ratio of 39.27, a P/E/G ratio of 3.62 and a beta of 0.83. The business's 50-day moving average price is $21.82 and its 200 day moving average price is $22.39. Kenvue Inc. has a 1-year low of $18.10 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm's quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 earnings per share. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 3.8%. Kenvue's dividend payout ratio (DPR) is presently 150.91%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KVUE shares. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Citigroup lowered their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Bank of America lowered their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Finally, Barclays lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday, July 15th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $24.79.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.